# A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma

> **NCT01317901** · PHASE1 · COMPLETED · sponsor: **Aptevo Therapeutics** · enrollment: 12 (actual)

## Conditions studied

- B-cell Small Lymphocytic Lymphoma Recurrent

## Interventions

- **DRUG:** TRU-016
- **DRUG:** Bendamustine
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT01317901
- **Lead sponsor:** Aptevo Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2013-04
- **Final completion:** 2013-06
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2017-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01317901

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01317901, "A Study of TRU-016 in Combination With Rituximab and Bendamustine in Subjects With Relapsed Indolent Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01317901. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*